USX:LOGC - LogicBio Therapeutics Inc (USD 4.51) LogicBio Therapeutics Inc
Sector: Health Technology, Industry: Medical Specialties
Add to Watchlist

Yahoo Finance

USD 4.51    +0.260 (+6.12%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

3 Apr 2020


3 Apr 2020

Day Change: 0.260 (6.12%)

52 Wk Range: 3.05 - 20.071

Day's Range: 4.02 - 4.51

Last Volume: 37,562

Current Yield: 0%

Projected Yield: 0%

Open: USD 4.02

3 Apr 2020

Metric LOGC S.Median
Beta 1.51 0.77
VaR 71.23 46.1
E.Shortfall 114.43 76.92
Liquidity 63.08K 22.95K


3 Apr 2020

PE: -2.866

Market Cap: 102.4M

Price Over Book: 1.924

Price Over Sales: NA

Return On Assets:

Return On Equity: -67.2%

NAV Over Price: [Friends Only]


CEO: Frederic Chereau

Employees: 23

Sector: Health Technology

Industry: Medical Specialties

Useful Links


LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.